New heart disease guidelines called into question
Cure for Celiac Coming?
PICTURE: Dr. Alessio Fasano, Victoria Kennedy, Dr. Ronald Kleinman, and Dr. Peter
Slavin have their picture taken by a Mass. General staff photographer
at the Museum of Medical History and Innovation.
When Leslie Williams, a former pharmaceutical executive, agreed to meet a visiting professor from Australia in Boston for a lecture, she thought it would be a routine lunch in her role as a business mentor.
But the meeting, three years ago at the Boston Cambridge Marriott, turned into an intense five-hour discussion as Dr. Robert Anderson explained how his research into celiac disease promised to render the destructive disorder obsolete.
An autoimmune disease triggered by gluten proteins in wheat, barley, and rye, celiac disease affects some 3 million Americans. Untreated, it can destroy digestive tract tissue and can lead to anemia, osteoporosis, infertility, neurological dysfunction, or even cancer.
Currently, the only solution is to avoid gluten altogether. That means not eating standard versions of bread, pasta, and pizza, or anything else that contains even traces of wheat, including soy sauce and some candy, such as Twizzlers.
But as Anderson explained that afternoon to Williams, his research was zeroing in on a vaccine to cure celiac disease.
The science “struck me as quite special and possibly game-changing,” Williams recalled.
She agreed to work with Anderson, and in short order Williams lined up seed capital from an angel investor and then went to Australia to unravel legal agreements around Anderson’s research and his company. Within the year, ImmusanT was formed, with Williams as chief executive and Anderson as chief scientific officer. By its first anniversary, the firm had $20 million in venture funding.
ImmusanT is headquartered in the biotech boomtown of Kendall Square in Cambridge and is conducting clinical trials for its vaccine, NexVax2, under “fast-track” designation from the Food and Drug Administration for diseases for which no comparable therapies exist.
“If it works, you’ll see the entire paradigm of treatment for celiac changed,” said Sundar Kodiyalam, managing director for the venture investor Vatera Healthcare and an ImmusanT board member. His firm was so enamored of the science that it invested before the company had persuasive clinical data.
Beyond ImmusanT, Boston has become a locus for research into celiac disease. Massachusetts General Hospital scored a coup when it recently convinced a leading researcher, Dr. Alessio Fasano, to head its new celiac treatment and research center. “Our mission is to make life normal for people with celiac disease,” Fasano said at a ceremony marking the opening of the Mass. General center in February.
With similar research units at Beth Israel Deaconess Medical Center and Children’s Hospital Boston, the city now has “a critical mass of expertise” in celiac disease, said Dr. Ronald Kleinman, physician in chief of Mass. General’s pediatric unit.
“I’m not sure that I see miracles happening” with the research underway now, said Lee Graham, chairwoman of Healthy Villi, a 900-member support group for celiac sufferers in New England. “But the gathering that’s happening in Boston is terrific, and tremendously encouraging to us.”
Formerly at the University of Maryland, Fasano in 2003 published a landmark analysis in which he determined that celiac disease affects many more people than previously thought: about 1 out of 100 people. Up to that point, the scientific wisdom was that celiac was relatively rare, and that a gluten-free diet worked as a sufficient “cure.”
But Fasano and others have since shown that some patients who avoid gluten continue to suffer gastric distress, leading to the conclusion that diet alone is not enough.
Not surprisingly, with the market for gluten-free foods at $4.2 billion, ImmunsanT has some company in the race for a solution.
Read the rest of the story HERE
When Leslie Williams, a former pharmaceutical executive, agreed to meet a visiting professor from Australia in Boston for a lecture, she thought it would be a routine lunch in her role as a business mentor.
But the meeting, three years ago at the Boston Cambridge Marriott, turned into an intense five-hour discussion as Dr. Robert Anderson explained how his research into celiac disease promised to render the destructive disorder obsolete.
An autoimmune disease triggered by gluten proteins in wheat, barley, and rye, celiac disease affects some 3 million Americans. Untreated, it can destroy digestive tract tissue and can lead to anemia, osteoporosis, infertility, neurological dysfunction, or even cancer.
Currently, the only solution is to avoid gluten altogether. That means not eating standard versions of bread, pasta, and pizza, or anything else that contains even traces of wheat, including soy sauce and some candy, such as Twizzlers.
The science “struck me as quite special and possibly game-changing,” Williams recalled.
She agreed to work with Anderson, and in short order Williams lined up seed capital from an angel investor and then went to Australia to unravel legal agreements around Anderson’s research and his company. Within the year, ImmusanT was formed, with Williams as chief executive and Anderson as chief scientific officer. By its first anniversary, the firm had $20 million in venture funding.
ImmusanT is headquartered in the biotech boomtown of Kendall Square in Cambridge and is conducting clinical trials for its vaccine, NexVax2, under “fast-track” designation from the Food and Drug Administration for diseases for which no comparable therapies exist.
“If it works, you’ll see the entire paradigm of treatment for celiac changed,” said Sundar Kodiyalam, managing director for the venture investor Vatera Healthcare and an ImmusanT board member. His firm was so enamored of the science that it invested before the company had persuasive clinical data.
Beyond ImmusanT, Boston has become a locus for research into celiac disease. Massachusetts General Hospital scored a coup when it recently convinced a leading researcher, Dr. Alessio Fasano, to head its new celiac treatment and research center. “Our mission is to make life normal for people with celiac disease,” Fasano said at a ceremony marking the opening of the Mass. General center in February.
With similar research units at Beth Israel Deaconess Medical Center and Children’s Hospital Boston, the city now has “a critical mass of expertise” in celiac disease, said Dr. Ronald Kleinman, physician in chief of Mass. General’s pediatric unit.
“I’m not sure that I see miracles happening” with the research underway now, said Lee Graham, chairwoman of Healthy Villi, a 900-member support group for celiac sufferers in New England. “But the gathering that’s happening in Boston is terrific, and tremendously encouraging to us.”
Formerly at the University of Maryland, Fasano in 2003 published a landmark analysis in which he determined that celiac disease affects many more people than previously thought: about 1 out of 100 people. Up to that point, the scientific wisdom was that celiac was relatively rare, and that a gluten-free diet worked as a sufficient “cure.”
But Fasano and others have since shown that some patients who avoid gluten continue to suffer gastric distress, leading to the conclusion that diet alone is not enough.
Not surprisingly, with the market for gluten-free foods at $4.2 billion, ImmunsanT has some company in the race for a solution.
Read the rest of the story HERE
Related articles
Superfish (Not Just Salmon) You Should Be Eating
Just about every nutrition expert recommends eating lots of fish
- at least once a week, preferably more often. The fish most often
cited to reduce risk of heart disease, cancer, Alzheimer's, and diabetes
is wild salmon. However, wild salmon is expensive, sometimes...
[Full Story]
Read Latest Breaking News from Newsmax.com http://www.newsmax.com/#ixzz2kOVvUets
Urgent: Should Obamacare Be Repealed? Vote Here Now!
Related articles
Anti-Testosterone Study Is Misleading, Overhyped: Top Doctor
Chemical Structure of Testosterone. (Photo credit: Wikipedia) |
A new headline-making study warning of dire side effects from
testosterone medications is misleading and has been overhyped, says a
top hormone therapy expert.
“I’m concerned that men will stop taking testosterone because of
this new study,” Erika Schwartz, M.D., told Newsmax Health. “It
contradicts all the previous research that shows the benefits of this
form of therapy. When taken properly, the results of testosterone
therapy can be amazing.”
The new research suggests that men who take testosterone after
undergoing a minor cardiac procedure are more likely to suffer strokes,
heart attacks, or die. The study was published in the Journal of the American Medical Association.
The findings directly contradict a similar study done last year, which
found that similarly aged men who took testosterone had a 50 percent
less risk of dying, noted Dr. Schwartz, a leading national expert who
has hosted a PBS special on hormone therapies.
The major difference between the two studies was the condition of
the subjects. Most of the men in the new study had serious health
problems, including a prior history of heart attack, congestive heart
failure, or confirmed coronary heart disease. Men in the previous study
were healthier.
“All this study showed was that older men with heart disease, who
are sick, are not likely to benefit from starting testosterone therapy.
It says nothing about the relatively healthy men who have benefited from
testosterone therapy and use it for prevention,” said Dr. Schwartz. “My
patients, if they start testosterone early enough, they benefit
tremendously.”
Read Latest Breaking News from Newsmax.com http://www.newsmaxhealth.com/Headline/testosterone-low-t-aging-dangers/2013/11/07/id/535445#ixzz2k3jjP5a8
Alert: What Is Your Risk for a Heart Attack? Find Out Now
More Coffee May Lead To A Longer Life
Written By:
Margie King, Health CoachAccording to a study in the New England Journal of Medicine, older adults who drink coffee have a lower risk of death overall than non-coffee drinkers. The coffee drinkers were less likely to die from heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections.
The study was conducted by researchers from the National Cancer Institute (NCI) and AARP. Over 13 years they examined the coffee drinking habits and risk of death in 400,000 U.S. men and women aged 50 to 71. The participants answered a questionnaire as part of the NIH-AARP Diet and Health Study from 1995 to 2008.
More coffee is better >>>>>>>>>> Read the rest>>>>>>>>
Related articles
- Drink Coffee, Protect Your Liver
- Coffee Drinkers May Have Lower Liver Cancer Risk
- Coffee's Incredible Health Benefits
- Coffee consumption cuts liver cancer risk
- What Your Coffee Says About You
- Costly Prostate Therapy Common When Docs Own the Machine
- Study: Low Estrogen May Play a Role in 'Male Menopause'
- Kosher chicken -- kosher but not necessarily safer
Harvard Researchers: Chocolate Protects Against Alzheimer's
This image was selected as a picture of the week on the Czech Wikipedia for th week, 2007. (Photo credit: Wikipedia) |
Here's some sweet health news for chocolate lovers: A daily dose of
the sugary treat may help prevent Alzheimer's disease. That's the
conclusion of new research at Harvard Medical School that found people
who drank two cups of hot cocoa a day had improved memory and blood flow
to the brain.
But the benefits only come from certain types of chocolate, which
contain high levels of beneficial antioxidants, notes one of the
nation's top Alzheimer's experts, Dr. Gary Small, professor of
psychiatry and aging. It's also important to know that you can get too
much of a good thing.
Special: Chocolate's 700 Year History of Healing
"I think it is healthy in moderation, that's the key because if you
drink too much cocoa or eat too many chocolate bars you’re going to
gain a lot of calories and that is not good for the brain," Dr. Small
tells Newsmax Health. "In fact it's the dark chocolates that are
particularly potent; milk chocolates have very little and white
chocolate has almost none. So if you want the antioxidant boost, go for
the dark chocolate."
Story continues below video.
Read Latest Breaking News from Newsmax.com http://www.newsmaxhealth.com/Health-News/chocolate-alzheimer-dementia-cocoa/2013/10/22/id/532369#ixzz2iXtQj1bK
Alert: What Is Your Risk for a Heart Attack? Find Out Now
Doctors Keep Quiet About Cancer Screening Dangers: Study
Doctors seldom tell patients about the possible harms of getting screened for cancer, a new study shows.
During any screening test, there is a chance of so-called
overdiagnosis - finding something that looks like cancer but isn't, or a
cancer that's so small and slow-growing it would never cause a
problem.
In those cases, patients may get biopsies, surgeries, radiation and
drugs that won't bring them any benefit, but could come with side
effects, known as overtreatment.
In those cases, patients may get biopsies, surgeries, radiation and drugs that won't bring them any benefit, but could come with side effects, known as overtreatment.
Read Latest Breaking News from Newsmax.com http://www.newsmaxhealth.com/Health-News/cancer-screening-risks-doctors/2013/10/21/id/532248#ixzz2iU9sJeaC
Alert: What Is Your Risk for a Heart Attack? Find Out Now
Related articles
- Doctors Rarely Discuss Risks of Cancer Screening
- Many People Not Told Cancer Tests Can Lead to 'Overtreatment'
- Patients report doctors not telling them of overdiagnosis risk in screenings
- Millions Wrongly Treated for 'Cancer,' National Cancer Institute Panel Confirms
- Baby Shampoo Contains 'Probable Human Carcinogen'
- Kosher chicken -- kosher but not necessarily safer
Pills made from poop cure serious gut infections
Scanning electron micrograph of Clostridium difficile bacteria from a stool sample. Obtained from the CDC Public Health Image Library. Image credit: CDC/ Lois S. Wiggs (PHIL #6260), 2004. (Photo credit: Wikipedia) |
By MARILYNN MARCHIONE
Hold
your nose and don't spit out your coffee: Doctors have found a way to
put healthy people's poop into pills that can cure serious gut
infections — a less yucky way to do "fecal transplants." Canadian
researchers tried this on 27 patients and cured them all after strong
antibiotics failed to help.
It's a gross
topic but a serious problem. Half a million Americans get Clostridium
difficile, or C-diff, infections each year, and about 14,000 die. The
germ causes nausea, cramping and diarrhea so bad it is often disabling. A
very potent and pricey antibiotic can kill C-diff but also destroys
good bacteria that live in the gut, leaving it more susceptible to
future infections.
Read more: http://www.myfoxny.com/Story/23600644/pills-made-from-poop-cure-serious-gut-infections#ixzz2iU91CJjG
Lyme, tick-borne illnesses get even more terrifying...
Lyme disease (Photo credit: monkeypuzzle) |
“This is a huge question,” said C. Ben Beard, chief of the Bacterial Diseases Branch of the US Centers for Disease Control and Prevention. “We really need to understand what is going on.”
Many Lyme sufferers and activists, and some doctors are convinced that the bacteria that cause the disease can, especially if not caught early, evade antibiotics and the body’s immune system by burrowing into joints, the nervous system, and other tissue to wreak sustained havoc.
Most infectious disease specialists, however, say there is a lack of convincing evidence for this persistent infection and that a month or less of antibiotics usually knocks the disease from the body. They suggest other causes: another illness or reinfection through a second tick bite. Or patients may have a syndrome triggered by Lyme that causes long-term fatigue or pain.
Underlying the emotional impasse is this simple fact: Lyme bacteria have rarely been found in patients after a cycle of antibiotics. Lyme tests look not for the bacteria but for antibodies...... MORE>>>>>>>>>
Related articles
Subscribe to:
Posts (Atom)